Identification

Summary

Stiripentol is an antiepileptic agent used in combination with other anticonvulsants to treat seizures associated with Dravet syndrome.

Brand Names
Diacomit
Generic Name
Stiripentol
DrugBank Accession Number
DB09118
Background

Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.2,6 The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes.6 However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood.1

Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.7,8,10 It is marketed under the brand name Diacomit.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 234.295
Monoisotopic: 234.12559444
Chemical Formula
C14H18O3
Synonyms
  • 1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol
  • 4,4-Dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol
  • Estiripentol
  • Stiripentol
  • Stiripentolum
External IDs
  • BCX 2600
  • BCX-2600
  • BRN 1313047

Pharmacology

Indication

In the US, stiripentol is indicated for the treatment of seizures associated with Dravet syndrome in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more. There are no clinical data to support the use of stiripentol as monotherapy in Dravet syndrome.8

In Europe and Canada, stiripentol is indicated for use as adjunctive therapy with clobazam and valproate to refractory generalized tonic-clonic seizures in patients with Dravet syndrome in infancy whose seizures are not adequately controlled with clobazam and valproate alone.7,10

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Stiripentol is an antiepileptic agent that works to reduce seizure frequency. It demonstrates anticonvulsant properties when administered alone and may potentiate GABAergic inhibition via several proposed mechanisms.4 It provides a therapeutic advantage in improving the efficacy of other antiepileptic drugs by inhibiting cytochrome P450 enzymes that normally metabolize those drugs.8 The anticonvulsant activity of stiripentol is age-dependent, with increased efficacy in younger patients.4

Mechanism of action

The mechanism by which stiripentol exerts its anticonvulsant effect in humans has not been fully elucidated. Possible mechanisms of action include direct effects mediated through the gamma-aminobutyric acid GABAA receptor and indirect effects involving inhibition of cytochrome P450 activity with a resulting increase in blood levels of clobazam and its active metabolite.8

Stiripentol is a positive allosteric modulator of GABAA receptors in the brain that enhances the opening duration of the channel by binding to a site different than the benzodiazepine binding site.1 It binds to GABAA receptors containing any of the α, β, γ, or δ-subunits but displays the most potent potency when bound to receptors containing α3 or δ subunits.4 Stiripentol also binds to GABAA receptor-dependent chloride channels via a barbiturate-like mechanism.5 Stiripentol potentiates GABA transmission by enhancing the release of GABA,1,2 reducing synaptosomal uptake of GABA,7 and inhibiting GABA transaminase-mediated breakdown of GABA.7

Stiripentol is an inhibitor of lactate dehydrogenase (LDH), which is involved in the energy metabolism of neurons and regulation of neuronal excitation. The drug binds to the site separate from the enzyme's lactate and pyruvate binding sites, thereby inhibiting both pyruvate-to-lactate conversion and lactate-to-pyruvate conversion.3 By inhibiting LDH, stiripentol may induce hyperpolarization, thereby reducing neuronal excitability.5 LDH inhibitors, including stiripentol, mimic a ketogenic diet, where the energy source in the brain is switched from glucose to mainly ketone bodies. The ketone bodies directly regulate neuronal excitation and seizures via ATP-sensitive potassium channels and vesicular glutamate transporters.3 Stiripentol is also suggested to exhibit neuroprotective properties, which may reduce injury caused by oxygen-glucose deprivation and glutamate excess.5

TargetActionsOrganism
AGABA(A) Receptor
agonist
positive allosteric modulator
Humans
AL-lactate dehydrogenase A chain
inhibitor
Humans
AL-lactate dehydrogenase B chain
inhibitor
Humans
Absorption

After oral administration, stiripentol is quickly and readily absorbed 2 with a median Tmax of two to three hours.8 The systemic exposure increases dose-proportionally.7 Stiripentol has a low bioavailability due to water insolubility and extensive metabolism.2

Volume of distribution

The average volume of distribution is 1.03 L/kg but does not display a dose-dependent relationship. Following administration, stiripentol enters the brain and accumulates in the cerebellum and medulla.2

Protein binding

Protein binding of stiripentol is 99%.8

Metabolism

Stiripentol is extensively metabolized. About 13 different metabolites have been found in urine. The main metabolic processes are demethylenation (oxidative cleavage of the methylenedioxy ring system) and glucuronidation, although precise identification of the enzymes involved has not yet been achieved.7,10 Other metabolic pathways include O-methylation of catechol metabolites, hydroxylation of the t-butyl group, and conversion of the allylic alcohol side-chain to the isomeric 3-pentanone structure.2

In vitro studies suggested that the phase I metabolism of stiripentol is catalyzed by CYP1A2, CYP2C19 and CYP3A4 and possibly other enzymes.10

Route of elimination

Stiripentol is mainly eliminated via metabolism.2 Its metabolites are excreted mainly via the kidney. Urinary metabolites of stiripentol accounted collectively for the majority (73%) of an oral acute dose whereas a further 13-24% was recovered in feces as unchanged drug.7

Half-life

The elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner.8

Clearance

Plasma clearance decreases markedly at high doses; it falls from approximately 40 L/kg/day at the dose of 600 mg/day to about 8 L/kg/day at the dose of 2,400 mg. Clearance is decreased after repeated administration of stiripentol, probably due to inhibition of the cytochrome P450 isoenzymes responsible for its metabolism.7

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

The oral LD50 in rats is >3 g/kg.9

There is limited clinical data on stiripentol overdose in humans. In mice, high doses of stiripentol (600 to 1800 mg/kg i.p.) caused decreased motor activity and respiration. Overdose should be managed with supportive and symptomatic treatment.8

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe metabolism of 1,2-Benzodiazepine can be decreased when combined with Stiripentol.
AbacavirAbacavir may decrease the excretion rate of Stiripentol which could result in a higher serum level.
AbametapirThe serum concentration of Stiripentol can be increased when it is combined with Abametapir.
AbataceptThe metabolism of Stiripentol can be increased when combined with Abatacept.
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Stiripentol.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Stiripentol.
AbrocitinibThe metabolism of Abrocitinib can be decreased when combined with Stiripentol.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Stiripentol.
AcebutololThe metabolism of Acebutolol can be decreased when combined with Stiripentol.
AceclofenacAceclofenac may decrease the excretion rate of Stiripentol which could result in a higher serum level.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid excessive or chronic alcohol consumption. Ingesting alcohol may increase the risk of sedation and somnolence that can be caused by stiripentol.
  • Avoid milk and dairy products. These products may interfere with the absorption of stiripentol.
  • Limit caffeine intake. Stiripentol may attenuate CYP1A2-mediated metabolism of caffeine.
  • Take with a full glass of water. Oral capsules should be swallowed whole with a glass of water during a meal and oral suspension should be mixed in a glass of water and should be taken immediately after mixing during a meal.
  • Take with food. Stiripentol degrades rapidly in an acidic environment.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DiacomitCapsule500 mgOralBiocodex2016-09-07Not applicableEU flag
DiacomitCapsule250 mgOralBiocodex2016-09-07Not applicableEU flag
DiacomitPowder, for suspension250 mg / sachetOralBiocodex Sa2013-05-01Not applicableCanada flag
DiacomitCapsule100 mgOralBiocodex2022-05-04Not applicableEU flag
DiacomitPowder, for suspension500 mg/1OralBIOCODEX, INC.2018-08-21Not applicableUS flag
DiacomitPowder, for suspension500 mgOralBiocodex2016-09-07Not applicableEU flag
DiacomitPowder, for suspension250 mgOralBiocodex2016-09-07Not applicableEU flag
DiacomitCapsule250 mg/1OralBIOCODEX, INC.2018-08-21Not applicableUS flag
DiacomitCapsule500 mgOralBiocodex2016-09-07Not applicableEU flag
DiacomitCapsule250 mgOralBiocodex2016-09-07Not applicableEU flag

Categories

ATC Codes
N03AX17 — Stiripentol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzodioxoles. These are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodioxoles
Sub Class
Not Available
Direct Parent
Benzodioxoles
Alternative Parents
Styrenes / Secondary alcohols / Oxacyclic compounds / Acetals / Hydrocarbon derivatives
Substituents
Acetal / Alcohol / Aromatic heteropolycyclic compound / Benzenoid / Benzodioxole / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Oxacycle / Secondary alcohol
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
R02XOT8V8I
CAS number
49763-96-4
InChI Key
IBLNKMRFIPWSOY-FNORWQNLSA-N
InChI
InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+
IUPAC Name
(1E)-1-(2H-1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
SMILES
CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1

References

General References
  1. Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H: Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16. [Article]
  2. Trojnar MK, Wojtal K, Trojnar MP, Czuczwar SJ: Stiripentol. A novel antiepileptic drug. Pharmacol Rep. 2005 Mar-Apr;57(2):154-60. [Article]
  3. Sada N, Lee S, Katsu T, Otsuki T, Inoue T: Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015 Mar 20;347(6228):1362-7. doi: 10.1126/science.aaa1299. [Article]
  4. Grosenbaugh DK, Mott DD: Stiripentol in refractory status epilepticus. Epilepsia. 2013 Sep;54 Suppl 6:103-5. doi: 10.1111/epi.12291. [Article]
  5. Frampton JE: Stiripentol: A Review in Dravet Syndrome. Drugs. 2019 Nov;79(16):1785-1796. doi: 10.1007/s40265-019-01204-y. [Article]
  6. Chiron C: Stiripentol. Neurotherapeutics. 2007 Jan;4(1):123-5. doi: 10.1016/j.nurt.2006.10.001. [Article]
  7. EMA Approved Drug Products: DIACOMIT (stiripentol) Oral Capsules [Link]
  8. FDA Approved Drug Products: DIACOMIT (stiripentol) suspension or capsules, for oral use [Link]
  9. Cayman Chemical: Stiripentol MSDS [Link]
  10. Health Canada Approved Drug Products: DIACOMIT (stiripentol) Oral Capsules or Powder for suspension [Link]
PubChem Compound
5311454
PubChem Substance
310265035
ChemSpider
4470940
BindingDB
50504273
RxNav
2054968
ChEMBL
CHEMBL1983350
Wikipedia
Stiripentol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentPharmacoresistant Focal Epilepsies1
4Unknown StatusTreatmentEpilepsies1
2CompletedTreatmentPrimary Hyperoxaluria1
1CompletedBasic ScienceHealthy Subjects (HS)1
Not AvailableApproved for MarketingNot AvailableDravet Syndrome (DS)1
Not AvailableNo Longer AvailableNot AvailableDravet Syndrome (DS)2
Not AvailableNo Longer AvailableNot AvailableDravet Syndrome (DS) / Epileptic Encephalopathies Associated With SCN1A Mutations1
Not AvailableRecruitingNot AvailableEpilepsies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral100 MG
CapsuleOral250 mg/1
CapsuleOral250 mg
CapsuleOral500 mg/1
CapsuleOral500 mg
Powder, for suspensionOral250 mg / sachet
Powder, for suspensionOral250 MG
Powder, for suspensionOral250 mg/1
Powder, for suspensionOral500 MG
Powder, for suspensionOral500 mg/1
Powder, for suspensionOral500 mg / sachet
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)73-74https://www.trc-canada.com/prod-img/MSDS/S686825MSDS.pdf
logP2.94https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206709s003;207223s003lbl.pdf
pKa14.2https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206709s003;207223s003lbl.pdf
Predicted Properties
PropertyValueSource
Water Solubility0.405 mg/mLALOGPS
logP3.01ALOGPS
logP3.12Chemaxon
logS-2.8ALOGPS
pKa (Strongest Acidic)14.34Chemaxon
pKa (Strongest Basic)-3.1Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area38.69 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity66.77 m3·mol-1Chemaxon
Polarizability26.21 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
Positive allosteric modulator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Fisher JL: The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology. 2009 Jan;56(1):190-7. doi: 10.1016/j.neuropharm.2008.06.004. Epub 2008 Jun 10. [Article]
  2. FDA Approved Drug Products: DIACOMIT (stiripentol) suspension or capsules, for oral use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nad binding
Specific Function
Not Available
Gene Name
LDHA
Uniprot ID
P00338
Uniprot Name
L-lactate dehydrogenase A chain
Molecular Weight
36688.465 Da
References
  1. Sada N, Lee S, Katsu T, Otsuki T, Inoue T: Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015 Mar 20;347(6228):1362-7. doi: 10.1126/science.aaa1299. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nad binding
Specific Function
Not Available
Gene Name
LDHB
Uniprot ID
P07195
Uniprot Name
L-lactate dehydrogenase B chain
Molecular Weight
36638.225 Da
References
  1. Sada N, Lee S, Katsu T, Otsuki T, Inoue T: Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015 Mar 20;347(6228):1362-7. doi: 10.1126/science.aaa1299. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. EMA Approved Drug Products: DIACOMIT (stiripentol) Oral Capsules [Link]
  2. FDA Approved Drug Products: DIACOMIT (stiripentol) suspension or capsules, for oral use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. EMA Approved Drug Products: DIACOMIT (stiripentol) Oral Capsules [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. EMA Approved Drug Products: DIACOMIT (stiripentol) Oral Capsules [Link]
  2. FDA Approved Drug Products: DIACOMIT (stiripentol) suspension or capsules, for oral use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Tran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin JM, Lepage F, Levy RH: Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997 Nov;62(5):490-504. doi: 10.1016/S0009-9236(97)90044-8. [Article]
  2. Chiron C: Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11. doi: 10.1517/13543784.14.7.905 . [Article]
  3. FDA Approved Drug Products: DIACOMIT (stiripentol) suspension or capsules, for oral use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Trojnar MK, Wojtal K, Trojnar MP, Czuczwar SJ: Stiripentol. A novel antiepileptic drug. Pharmacol Rep. 2005 Mar-Apr;57(2):154-60. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. FDA Approved Drug Products: DIACOMIT (stiripentol) suspension or capsules, for oral use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. FDA Approved Drug Products: DIACOMIT (stiripentol) suspension or capsules, for oral use [Link]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. FDA Approved Drug Products: DIACOMIT (stiripentol) suspension or capsules, for oral use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. FDA Approved Drug Products: DIACOMIT (stiripentol) suspension or capsules, for oral use [Link]

Drug created at September 22, 2015 19:59 / Updated at December 04, 2022 18:48